This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform And A Rapidly Ageing Population Provide Strong Stimulus For Growth

NEW YORK, March 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth http://www.reportlinker.com/p01154051/China-Pharmaceutical-Market-Outlook---Government-Incentives-Healthcare-Reform-and-a-Rapidly-Ageing-Population-Provide-Strong-Stimulus-for-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth

Summary

GBI Research's new report: "China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth" provides in-depth analysis of the trends, issues and challenges facing the Chinese pharmaceutical market. It details the macroeconomic environment of China, providing a background of the financial and demographic situations in the country, as well as identifying key demographics. It covers the pharmaceutical market broken down by market segment, and the popularity of biosimilars and biologics, identifying where the strongest market potentials lie. It includes information on the regulatory guidelines for the manufacture, development and distribution of pharmaceuticals. The report also covers information on the competitive landscape in the Chinese pharmaceutical market, identifying market leaders and key trends in investment. It also includes the key drivers and barriers of the pharmaceutical market in more detail. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

China is currently one of the most important markets in the pharmaceutical industry. It is the most populous country in the world, with a recorded population of over 1.34 billion as of 2011. The country has the second-largest economy after the US with a GDP of $7.3 trillion as of 2011, and its economy is one of the fastest growing in the world, with average growth of 10.6% over the last decade (World Bank, 2012). China is the world's largest exporter and second-largest importer of goods.

In 2011, China overtook Germany to become the third largest pharmaceutical market in the world, and is predicted to overtake Japan by 2015 to become the second largest. In 2011, its estimated value was approximately $64 billion. The size of China's pharmaceutical market is primarily a result of its large population rather than its maturity, as it is still an emerging market. The Chinese pharmaceutical market has the world's largest manufacturing capabilities, producing more than 4,500 drugs and exporting various pharmaceutical products such as acetylsalicylic acid and metamizole to the global market. Recent healthcare reforms have been driving the pharmaceutical market by increasing public access to drugs. In addition, recent population changes such as a majority move from rural to urban China, a rapidly aging community and an increasing overweight population are driving the value of the Chinese pharmaceutical market.

Scope

The report analyzes the Chinese pharmaceutical market, looking at - - Macroeconomic analysis of China covering economic, demographic and market-specific indicators- Market analysis of segments such as branded and generic drugs, prescribed and OTC drugs, and biopharmaceuticals- Industry landscape, looking at pharmaceutical pricing policies, supply chain, drug regulations and healthcare reforms- Competitive profiling of major domestic and international companies operating in the Chinese pharmaceutical market in addition to the important M&A deals in recent years- Drivers and barriers of the Chinese pharmaceutical market

Reasons to buy

The report will enhance your decision-making capability by allowing you to - - Develop market-entry and market-expansion strategies by identifying the leading segments poised for strong growth- Devise a more tailored country strategy through understanding key drivers of and barriers to the pharmaceutical market- Develop key strategic initiatives by understanding leading companies' key focus areas- Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs